Evidence map›Paper›PMID 33256658›Full record

SynthesisBMC cancer2020

The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis.

Lilong Zhang, Qihang Yuan, Man Li, Dongqi Chai, Wenhong Deng, Weixing Wang

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Assessment of Adipokine and Inflammation Biomarkers with Cancer Risk among Chinese Men: A Prospective Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Update on Adipose Tissue and Cancer.Endocrine reviews · 2023
    Article
  13. Review
  14. Review
  15. Obesity and cancer: focus on leptin.Molecular biology reports · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lilong ZhangDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
Qihang YuanDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, Liaoning, China.
Man LiDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
Dongqi ChaiDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China.
Wenhong DengDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. wenhongdeng@whu.edu.cn.
Weixing WangDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. sate.llite@163.com.ORCID http://orcid.org/0000-0002-3854-0083
Wuhan University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting.

methodsA meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data.

resultsThirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (- 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = - 0.51, 95% CI (- 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766).

conclusionThe study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis.

Indexed as

AdiponectinCarcinoma, HepatocellularHumansLeptinLiver NeoplasmsPrognosisSurvival AnalysisAdiponectinLeptinAdiponectinHepatocellular carcinomaLeptinMeta-analysis

Identifiers

PMID33256658
PMCPMC7708253
OpenAlexW3109665042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.